Clinical Trials · NCT05757531
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 7
- Start date
- Mar 2023
- Locations
- 1 site, United States
- Primary endpoint
- Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered